Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OBIO 
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: OBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.67% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.44M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 7 | Beta 0.65 | 52 Weeks Range 2.20 - 6.50 | Updated Date 11/11/2025 |
52 Weeks Range 2.20 - 6.50 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2311.84% |
Management Effectiveness
Return on Assets (TTM) -77.32% | Return on Equity (TTM) -313.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 197560625 | Price to Sales(TTM) 72.5 |
Enterprise Value 197560625 | Price to Sales(TTM) 72.5 | ||
Enterprise Value to Revenue 67.11 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 56464731 | Shares Floating 32071982 |
Shares Outstanding 56464731 | Shares Floating 32071982 | ||
Percent Insiders 16.03 | Percent Institutions 35.69 |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings Inc. (OBIO) is a biomedical innovation company focused on developing transformative therapies for high-impact diseases. The company was founded with the goal of creating innovative solutions to address unmet medical needs in cardiovascular disease and other areas. They have grown through acquisitions and strategic partnerships to expand their product pipeline and technology platforms.
Core Business Areas
- BackBeat CNT: A neuromodulation therapy designed to lower blood pressure. It stimulates the vagus nerve to modulate autonomic balance and reduce hypertension.
- Virtue SABA: A sustained anti-restenotic balloon angioplasty (SABA) for the treatment of atherosclerotic disease. It provides a sustained release of sirolimus during angioplasty.
Leadership and Structure
The leadership team includes key executives with expertise in medical device development, regulatory affairs, and commercialization. The company has a board of directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- BackBeat CNT: A neuromodulation therapy for hypertension. Market share data is not readily available. Competitors include companies developing similar neuromodulation therapies or hypertension drugs. Examples include Medtronic with their renal denervation system. No revenue data from this product available.
- Virtue SABA: A sustained anti-restenotic balloon angioplasty (SABA) for treatment of atherosclerotic disease. Market share data is not readily available. Competitors include companies manufacturing drug-eluting balloons. No revenue data from this product available.
Market Dynamics
Industry Overview
The biomedical industry is rapidly evolving with advancements in medical devices, therapies, and diagnostics. There is a growing demand for innovative solutions to address chronic diseases and improve patient outcomes.
Positioning
Orchestra BioMed Holdings Inc. is positioned as an innovator in the biomedical space with its novel neuromodulation and drug-eluting technologies. Competitive advantages lie in its proprietary technology platforms and focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for hypertension and atherosclerotic disease treatments is substantial, reaching billions of dollars globally. Orchestra BioMed is positioned to capture a portion of this TAM through its novel therapies, but its success depends on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Innovative technology platforms
- Focus on unmet medical needs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- Dependence on clinical trial success
- High R&D expenses
- Relatively small size compared to industry giants
Opportunities
- Expanding product pipeline through acquisitions and partnerships
- Securing regulatory approvals for key products
- Entering new markets
- Capitalizing on growing demand for innovative therapies
Threats
- Competition from larger companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- MDGN
- BSX
- ABT
Competitive Landscape
Orchestra BioMed faces competition from larger, more established medical device companies. Its advantages lie in its novel technologies, while its disadvantages stem from its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trajectory is dependent on clinical trial outcomes and commercialization efforts.
Future Projections: Future growth projections are based on analyst estimates of revenue from BackBeat CNT and Virtue SABA.
Recent Initiatives: Recent initiatives include advancing clinical trials for BackBeat CNT and Virtue SABA and seeking regulatory approvals.
Summary
Orchestra BioMed Holdings Inc. is a biomedical company with innovative technologies targeting hypertension and atherosclerotic disease. Its success hinges on positive clinical trial results and securing regulatory approvals for its key products. While the company faces competition from larger players, its focus on unmet medical needs and proprietary technologies could drive future growth. Close monitoring of financial performance, R&D spending, and market dynamics is essential. The company should capitalize on strategic partnership and acquisitions to sustain long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where available)
- Analyst Reports (where available)
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share and financial data are estimates based on publicly available information and may not be exact. Investment decisions should be based on thorough due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://orchestrabiomed.com |
Full time employees 70 | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.